MBXHealthcare · BiotechnologyMBX Stock Forecast: MBX Biosciences, Inc. Price Predictions for 2026-2027
The 11 Wall Street analysts covering MBX Biosciences, Inc. hold a median 12-month price target of $84 — +30.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 1 Aug 2026 — in the lower half.
MBX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores MBX Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Volatility (14): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own MBX Biosciences, Inc. — and when they’d sell — is the membership.
MBX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MBX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +30.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | Mizuho | Maintains | Outperform | $57 → $91 |
| 12 May 2026 | Barclays | Maintains | Overweight | $66 → $70 |
| 12 May 2026 | Barclays | Maintains | Overweight | — |
| 12 May 2026 | Citizens | Maintains | Market Outperform | $76 → $86 |
| 12 May 2026 | Citizens | Maintains | Market Outperform | — |
| 11 May 2026 | Truist Securities | Maintains | Buy | $50 → $70 |
| 11 May 2026 | Truist Securities | Maintains | Buy | — |
| 28 Jan 2026 | Barclays | Initiates | Overweight | — |
| 16 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 7 Jan 2026 | UBS | Initiates | Buy | — |
| 19 Dec 2025 | Stifel | Maintains | Buy | — |
| 4 Dec 2025 | Goldman Sachs | Initiates | Sell | — |
| 10 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 4 Nov 2025 | TD Cowen | Initiates | Buy | — |
| 15 Oct 2025 | Truist Securities | Initiates | Buy | — |
| 24 Sept 2025 | Mizuho | Maintains | Outperform | — |
| 23 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 23 Sept 2025 | Oppenheimer | Maintains | Outperform | — |
| 15 Aug 2025 | Jefferies | Assumes | Buy | $36 |
| 5 Aug 2025 | Mizuho | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MBX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
MBX Biosciences, Inc. (MBX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 3.7×
- Price / sales
- —
- Price / book
- 7.2×
- EV / EBITDA
- −27.4×
Cheaper than 67% of US stocks
Cheaper than 14% of US stocks
Cheaper than 91% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −25.7%
- Return on assets
- −17.7%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MBX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBX appears on the weeks it earns a place.
Frequently asked questions about MBX stock
What is the MBX stock price forecast for 2026-2027?
The 11 Wall Street analysts covering MBX Biosciences, Inc. have a median 12-month price target of $84, with estimates ranging from $56 to $91. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MBX stock a buy right now?
Of the 11 analysts covering MBX Biosciences, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MBX Biosciences, Inc. 41 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MBX?
As at 1 Aug 2026, MBX Biosciences, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
Will MBX stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts implies +30.4% from the last close, and Ticker Nerd's factor model ranks MBX Biosciences, Inc. 41 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MBX stock forecast for 2030?
No analyst covering MBX Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $91 over the next 12 months.
How has MBX stock performed over the past year?
MBX Biosciences, Inc. returned +368.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MBX Biosciences, Inc. do?
Mbx Biosciences Inc. is a biopharmaceutical company focused on the research and development of innovative endocrine therapeutics.
About MBX Biosciences, Inc.
Mbx Biosciences Inc. is a biopharmaceutical company focused on the research and development of innovative endocrine therapeutics. It strives to address unmet medical needs through pioneering treatments for endocrine disorders. The company's central aim is to develop precision endocrinology therapies, leveraging proprietary technologies to create treatment options that are more precise and effective for specific patient populations. Mbx Biosciences operates at the intersection of biotechnology and healthcare, significantly impacting the health sector by working towards solutions that can transform the management of hormonal disorders. In terms of market significance, Mbx Biosciences represents the advancing frontier of personalized medicine, emphasizing targeted therapies that promise improved outcomes and quality of life for patients suffering from conditions related to hormonal imbalances. By contributing to the biopharmaceutical landscape with innovative solutions, it holds a vital role in advancing both the scientific understanding and therapeutic interventions in endocrine health.
CEO Mr. Peter Kent Hawryluk MBA · 63 employees · United States · https://mbxbio.com